Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (441-450 of 527) with videos related to

Pageof 53
Sort By:
Liver Cancer|November 1, 2021
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)Masatoshi Kudo, Richard S Finn, Manabu Morimoto, et al.
Journal of Hepatology|December 13, 2021
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaAnn-Lii Cheng, Shukui Qin, Masafumi Ikeda, et al.
The Science of the Total Environment|April 29, 2015
Human effects on ecological connectivity in aquatic ecosystems: Integrating scientific approaches to support management and mitigationDavid A Crook, Winsor H Lowe, Frederick W Allendorf, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
The Lancet. Oncology|December 20, 2014
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyRichard S Finn, John P Crown, Istvan Lang, et al.
Nature. Mental Health|May 15, 2026
Optimizing functional connectivity scanning conditions for predicting autistic traitsCorey Horien, Francesca Mandino, Abigail S Greene, et al.
The Journal of Experimental Medicine|March 16, 2021
Germline SAMD9L truncation variants trigger global translational repressionEric J Allenspach, Frank Soveg, Laura S Finn, et al.
NPJ Breast Cancer|July 1, 2024
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studiesMaggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, et al.
ESMO Open|May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinomaR S Finn, M Kudo, P Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Pageof 53

Showing results (441-450 of 527) with videos related to

Sort By:
Pageof 53
Liver Cancer|November 1, 2021
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)Masatoshi Kudo, Richard S Finn, Manabu Morimoto, et al.
Journal of Hepatology|December 13, 2021
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaAnn-Lii Cheng, Shukui Qin, Masafumi Ikeda, et al.
The Science of the Total Environment|April 29, 2015
Human effects on ecological connectivity in aquatic ecosystems: Integrating scientific approaches to support management and mitigationDavid A Crook, Winsor H Lowe, Frederick W Allendorf, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
The Lancet. Oncology|December 20, 2014
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyRichard S Finn, John P Crown, Istvan Lang, et al.
Nature. Mental Health|May 15, 2026
Optimizing functional connectivity scanning conditions for predicting autistic traitsCorey Horien, Francesca Mandino, Abigail S Greene, et al.
The Journal of Experimental Medicine|March 16, 2021
Germline SAMD9L truncation variants trigger global translational repressionEric J Allenspach, Frank Soveg, Laura S Finn, et al.
NPJ Breast Cancer|July 1, 2024
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studiesMaggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, et al.
ESMO Open|May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinomaR S Finn, M Kudo, P Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Pageof 53